ScoreWhy is Beryl Drugs Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 7.27%
- Poor long term growth as Net Sales has grown by an annual rate of 11.44% and Operating profit at 10.53% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.82
2
Flat results in Sep 25
- EPS(Q) Lowest at Rs 0.02
3
Underperformed the market in the last 1 year
- Even though the market (BSE500) has generated returns of 2.12% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -34.89% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Beryl Drugs for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Beryl Drugs
-34.89%
-0.55
63.32%
Sensex
4.83%
0.41
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
11.44%
EBIT Growth (5y)
10.53%
EBIT to Interest (avg)
0.82
Debt to EBITDA (avg)
2.81
Net Debt to Equity (avg)
0.34
Sales to Capital Employed (avg)
1.53
Tax Ratio
61.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.01%
ROE (avg)
4.99%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
48
Industry P/E
34
Price to Book Value
1.16
EV to EBIT
14.30
EV to EBITDA
6.06
EV to Capital Employed
1.12
EV to Sales
0.69
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
10.96%
ROE (Latest)
2.42%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
OPERATING CF(Y)
Highest at Rs 2.64 Cr
PAT(9M)
Higher at Rs 0.18 Cr
PBDIT(Q)
Highest at Rs 0.73 cr.
PBT LESS OI(Q)
Highest at Rs 0.26 cr.
-1What is not working for the Company
EPS(Q)
Lowest at Rs 0.02
Loading Valuation Snapshot...
Here's what is working for Beryl Drugs
Operating Cash Flow - Annually
Highest at Rs 2.64 Cr
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 0.73 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 0.26 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Nine Monthly
Higher at Rs 0.18 Cr
than preceding 12 month period ended Sep 2025 of Rs 0.08 crMOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
PAT (Rs Cr)
Here's what is not working for Beryl Drugs
Earnings per Share (EPS) - Quarterly
Lowest at Rs 0.02
in the last five quartersMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
